首页> 外国专利> Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment

Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment

机译:评价共济失调毛细血管扩张症患者对糖皮质激素治疗反应的方法

摘要

The present invention relates to a novel procedure for evaluating the response of patients affected by Ataxia Talangiectasia (A-T) to glucocorticoids treatment. In particular, the procedure provides a step of qualitative and/or quantitative identification in the blood of said patients of the expression of a mRNA variant of the ATM (Ataxia-Talangiectasia-Mutated) gene produced by non-canonical splicing induced by glucocorticoid (GC). In fact, it was demonstrated that mRNA variant expression is present in the blood of patients who responded positively to treatment with GC.
机译:本发明涉及一种用于评估受共济失调性毛细血管扩张症(A-T)影响的患者对糖皮质激素治疗的反应的新颖方法。特别地,该程序提供了在所述患者的血液中定性和/或定量鉴定由糖皮质激素(GC)诱导的非规范性剪接产生的ATM(共济失调-毛细血管扩张-突变)基因的mRNA变体表达的步骤。 )。实际上,已证明mRNA变体表达存在于对GC治疗产生积极反应的患者的血液中。

著录项

  • 公开/公告号US10619208B2

    专利类型

  • 公开/公告日2020-04-14

    原文格式PDF

  • 申请/专利权人 ERYDEL S.P.A.;

    申请/专利号US201615544487

  • 申请日2016-01-19

  • 分类号C12Q1/68;C07H21/04;C12Q1/6883;C12Q1/6806;

  • 国家 US

  • 入库时间 2022-08-21 11:30:49

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号